Amble vs NexLife
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Amble
Best for mainstream telehealth GLP-1 accessStarting at $179/mo
NexLife
Best for pharmacy-quality-conscious patients seeking LegitScript + NABP-certified compounded GLP-1Starting at $145/mo
Side-by-Side Comparison
| Feature | Amble | NexLife |
|---|---|---|
| Overall Score | ✓7.4/10 | 7.0/10 |
| Starting Price | $179/mo | ✓$145/mo |
| Editorial Rating | ✓3.7 ★ /5 | 3.5 ★ /5 |
| Features | 3 features | ✓4 features |
| States Available | ✓50 | 0 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | — | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
Amble
Pros
- ✓Both semaglutide and tirzepatide available
- ✓Compounded GLP-1 access
Cons
- ✗Limited public information on program details
NexLife
Pros
- ✓LegitScript certified platform
- ✓Works exclusively with LegitScript-certified, NABP-accredited pharmacies — strongest pharmacy trust signal in the dataset
- ✓Both semaglutide and tirzepatide at competitive pricing
- ✓Semaglutide from $145/mo — among the lowest in the dataset
Cons
- ✗State availability not publicly disclosed
- ✗Pricing page returns 404 — exact tier pricing gated
- ✗Compounded only — no brand-name options
- ✗Also covers hormone optimization and longevity
Our Verdict
Amble edges out NexLife with a higher overall score of 7.4/10 and is particularly strong for mainstream telehealth GLP-1 access. NexLife remains a solid alternative, especially if you're looking for pharmacy-quality-conscious patients seeking LegitScript + NABP-certified compounded GLP-1.
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.